BioCentury
ARTICLE | Company News

Celgene sales and marketing update

May 2, 2016 7:00 AM UTC

The U.K.’s NICE recommended against the use of Vidaza azacitidine from Celgene to treat patients at least 65 years of age who are not eligible for hematopoietic stem cell transplantation (HSCT) with acute myelogenous leukemia (AML) with more than 30% bone marrow blasts. The agency said azacitidine failed to reach statistical significance compared to the combined conventional care regimen and therefore the degree to which it was more effective was “very uncertain.” NICE also estimated the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained at L240,000 ($345,888). ...